Kymera Therapeutics (KYMR) Company Report

Kymera Therapeutics focuses on targeted protein degradation within immunology markets.
The company has initiated its Phase 2B AD study for the STAT6 program and plans to start a Phase 2B asthma study in Q1 2026. Data from the Phase 1B study will be shared in December 2025, with Phase 2B AD data expected by mid-2027.
Kymera's IRF5 program, a wholly-owned asset targeting diseases like lupus, rheumatoid arthritis, and inflammatory bowel disease, is set to enter Phase 1 healthy volunteer studies in early 2026, with data expected in the same period.
The STAT6 program's safety profile is anticipated to be similar to Dupixent, with placebo-like safety observed in Phase 1A healthy volunteer studies.

12 hours ago

Transcript

Kymera Therapeutics Provides Updates on STAT6 and IRF5 Clinical Programs

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics is focused on its STAT6 program, with Phase 1b data expected to be shared this month.
The STAT6 Phase 2b AD study has commenced, and the Phase 2b asthma study is set to begin in Q1 next year. Data from the Phase 2b AD study is anticipated by mid-2027.
The company's IRF5 program will advance into Phase 1 healthy volunteer studies early next year, with a data readout also expected early next year.

13 hours ago

Transcript

Kymera Therapeutics Provides Pipeline Update and Strategic Outlook

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics, a leader in targeted protein degradation, is nearing its 10-year anniversary in May and has a pipeline focused on immunology, including wholly-owned STAT6 and IRF5 programs, and partnered programs with Sanofi and Gilead.
The STAT6 program (621) expects Phase 1b data readout this month (December 2025), has initiated its Phase 2b AD study, and plans to start a Phase 2b asthma study in Q1 2026. The company anticipates the first Phase 2b data by mid-2027.
Kymera has made a strategic decision to not partner the STAT6 program at this time, aiming to fully execute on the Phase 2b studies and potentially commercialize it themselves.
The IRF5 program has completed IND-enabling studies and is planned to move into Phase 1 early next year (2026), with a Phase 1 readout from healthy volunteers expected next year, followed by patient studies, prioritizing lupus.
The company reports $980 million in cash, providing a runway into the second half of 2028, which covers both STAT6 Phase 2b studies, starting the first Phase 3 study for STAT6, and advancing other pipeline programs, including IRF5.

1 day ago

Transcript

Kymera Therapeutics Provides Pipeline and Financial Update

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics is advancing its STAT6 program (621), with Phase 2b studies for atopic dermatitis and asthma underway, and the first data expected by mid-2027. The company has strategically decided to not partner this program at this stage, aiming to independently advance it through these studies.
The company's IRF5 program is poised to enter the clinic in 2026, with data anticipated next year.
Kymera reported $980 million in cash, providing a financial runway into the second half of 2028, which is expected to fund both Phase 2b studies, the start of the first Phase 3 study for STAT6, and the IRF5 program.

1 day ago

Transcript

Kymera Therapeutics Provides Pipeline Update and Financial Outlook at Citi Global Healthcare Conference

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics' STAT6 program (621) is expecting Phase I-B data readout this month (December 2025) in atopic dermatitis, with objectives to demonstrate Dupi-like efficacy on TH2 biomarkers and clinical endpoints at 28 days.
The company has initiated its Phase II-AD study for 621 and plans to start a Phase II-B asthma study in Q1 2026, with the first Phase II-B data anticipated by mid-2027.
Kymera maintains a strategic decision against partnering the STAT6 program, aiming to control its development and accelerate its path to market.
The IRF5 program, a wholly-owned immunology asset, has completed IND-enabling studies and is planned to enter Phase 1 early next year (2026), with a Phase 1 readout from healthy volunteers expected next year.
Kymera Therapeutics reports a strong financial position with $980 million in cash, providing a runway into the second half of 2028, which covers both STAT6 Phase II-B studies, the start of the first Phase III study, and other pipeline programs.

1 day ago

Transcript

Kymera Therapeutics Provides Pipeline and Partnership Updates

KYMR

New Projects/Investments

Guidance Update

Product Launch

Kymera Therapeutics is presenting Phase 1b broadened data on its STAT6 degrader, KT-621, and has initiated Phase 2b studies in atopic dermatitis with data expected by mid-2027. Phase 2b studies in asthma are on track to start in Q1 2026.
The company is preparing to advance its IRF5 degrader, KT-579, into the clinic in early 2026, with data anticipated in the second half of 2026.
Kymera maintains strong partnerships, including with Sanofi for the IRAK4 degrader KT-485, which Sanofi will start Phase 1 studies for in 2026, and a new deal with Gilead for a CDK2 molecular glue degrader.
Kymera ended the third quarter with $979 million in cash, providing a financial runway into the second half of 2028, enabling the funding of key clinical trials and new program advancements.

2 days ago

Transcript

Kymera Provides Updates on Clinical Pipeline and Financial Outlook

KYMR

New Projects/Investments

Guidance Update

Product Launch

Kymera is preparing to present Phase 1b broadened data for its STAT6 degrader, KT-621, and has initiated Phase 2b studies in atopic dermatitis, with data expected by mid-2027. Phase 2b studies for asthma are on track to start in Q1 2026.
The company plans to advance its IRF5 degrader, KT-579, into the clinic early next year (2026), with data anticipated in the second half of 2026.
Kymera maintains strong partnerships, including with Sanofi for the IRAK4 degrader KT-485, which Sanofi will start a Phase 1 study for next year (2026), and a new deal with Gilead for a CDK2 molecular glue degrader, which includes $750 million in potential milestones and royalties for Kymera.
The company ended the third quarter with $979 million in cash, providing a financial runway into the second half of 2028.

2 days ago

Transcript

Kymera Therapeutics Provides Pipeline and Financial Update

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics is advancing its lead protein degrader, KT-621 (STAT6 degrader), with Phase I-B data expected soon, Phase II-B studies initiated in atopic dermatitis (data by mid-2027), and a Phase II-B study in asthma on track to start in Q1 2026.
The company is preparing to advance KT-579 (IRF5 degrader) into the clinic early next year (2026), with data anticipated in H2 2026.
Kymera has strong partnerships, including Sanofi, which will start a Phase I study for the next-generation IRAK4 degrader KT-485 next year (2026), and a new deal with Gilead for a CDK2 molecular glue degrader with potential $750 million in milestones.
Kymera ended Q3 with $979 million in cash, providing a financial runway into the second half of 2028 to support multiple clinical milestones, including phase II-B studies, phase III initiation, and IRF5 proof-of-concept.

2 days ago

Transcript

Kymera Therapeutics Discusses Immunology Pipeline and Financial Runway

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics is focused on developing a new generation of medicines using targeted protein degradation, primarily in immunology, aiming for biologic-like efficacy with oral drug convenience.
The company anticipates releasing Phase 1b Atopic Dermatitis data for its STAT6 degrader (KT-621) in December. They plan to initiate parallel Phase 2b studies for Atopic Dermatitis and asthma.
Kymera's IRF5 program, targeting an undrugged transcription factor for diseases like lupus, RA, and IBD, is slated to begin Phase 1 early next year.
As of the last quarter, Kymera reported approximately $980 million in cash, which is projected to fund operations into the second half of 2028, covering key clinical milestones.

Nov 19, 2025, 11:00 AM

Transcript

Kymera Therapeutics Provides Update on Clinical Programs and Financial Position

KYMR

New Projects/Investments

Guidance Update

Kymera Therapeutics is focused on developing a new generation of oral medicines using targeted protein degradation, primarily in immunology, aiming for the efficacy of biologics with the convenience of oral drugs.
The company is advancing its STAT6 degrader (KT-621), with Phase 1b atopic dermatitis data expected in December. Healthy volunteer data demonstrated over 90% STAT6 degradation safely, leading to pathway inhibition comparable to upstream biologics.
Kymera plans to initiate two parallel dose-ranging Phase 2b studies for atopic dermatitis and asthma for KT-621.
The IRF5 program, targeting lupus and other type I interferon pathologies, is expected to start Phase 1 early next year (2026), with data anticipated next year.
Kymera reported a cash position of approximately $980 million as of the last quarter, providing a cash runway into the second half of 2028.

Nov 19, 2025, 11:00 AM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Kymera Therapeutics.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Nello Mainolfi say about margins?What are Kymera Therapeutics's strategic priorities?How is Kymera Therapeutics positioned vs competitors?How did Kymera Therapeutics do last quarter?

Let Fintool AI Agent track Kymera Therapeutics's earnings for you

Get instant analysis when filings drop